Real-world evidence points to NOAC benefits
Results from large phase III trials of NOACs for non-valvular atrial fibrillation are now being reflected in real-world data, a leading cardiology professor reports.
“What we’ve seen in RCTs now resonates in real-world evidence,” says John Camm, a professor of clinical cardiology at St George’s University of London.
Real-world data on the risks and benefits of NOACs is critical to inform evidence-based clinical practice, he says.
For the most part, such studies show that NOACs provide around the same stroke prevention as warfarin, but mostly cause less